Immunome, Inc. (NASDAQ:IMNM) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $34.25.

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Thursday, October 15th. Wedbush restated an “outperform” rating and issued a $35.00 target price on shares of Immunome in a research note on Tuesday, October 27th. Alliance Global Partners started coverage on Immunome in a report on Monday, September 21st. They set a “buy” rating and a $32.00 target price on the stock. William Blair initiated coverage on Immunome in a report on Friday, October 16th. They set an “outperform” rating on the stock. Finally, Truist Financial raised their price objective on shares of Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th.

Immunome Price Performance

NASDAQ:IMNM opened at $18.71 on Friday. The company’s fifty day moving average price is $21.49 and its 200-day moving average price is $22.40. Immunome has a 1-year low of $14.64 and a 1-year high of $30.06. The firm has a market capitalization of $2.13 billion, a P/E ratio of -7.40 and a beta of 2.68.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.14). Equities analysts anticipate that Immunome will post -2.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Isaac Barchas sold 11,048 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $27.25, for a total transaction of $301,058.00. Following the completion of the transaction, the director directly owned 92,211 shares of the company’s stock, valued at $2,512,749.75. This represents a 10.70% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Jack Higgins sold 13,200 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $25.32, for a total transaction of $334,224.00. Following the transaction, the insider owned 65,050 shares of the company’s stock, valued at $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 96,664 shares of company stock worth $2,533,134 over the last three months. 7.21% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMNM. Russell Investments Group Ltd. grew its stake in Immunome by 213.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 93,946 shares of the company’s stock valued at $2,021,000 after acquiring an additional 63,985 shares in the last quarter. Three Bridge Wealth Advisors LLC purchased a new position in Immunome in the 3rd quarter worth approximately $164,000. Alps Advisors Inc. lifted its stake in Immunome by 31.5% in the 3rd quarter. Alps Advisors Inc. now owns 150,502 shares of the company’s stock worth $3,237,000 after purchasing an additional 36,062 shares in the last quarter. Sterling Capital Management LLC lifted its stake in Immunome by 840.0% in the 3rd quarter. Sterling Capital Management LLC now owns 3,478 shares of the company’s stock worth $75,000 after purchasing an additional 3,108 shares in the last quarter. Finally, GK Wealth Management LLC acquired a new position in shares of Immunome during the 3rd quarter worth approximately $71,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc (NASDAQ: IMNM) is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based medicines. Its technology platform analyzes human immune responses to identify antibodies that may be developed into therapies for serious diseases.

The company’s research activities have included therapeutic programs in oncology and immunology, with an emphasis on antibodies designed to affect disease-driving biological pathways. Immunome has also conducted antibody discovery work related to infectious diseases, including SARS-CoV-2, as it has expanded its focus toward broader therapeutic applications.

Immunome is headquartered in Exton, Pennsylvania, and serves the global biopharmaceutical market through internal research and development activities and potential collaborations.